Lakefront Biotherapeutics (LKFT) Earnings Analysis

Lakefront Biotherapeutics (LKFT) next reports earnings on 2026-08-10, consensus EPS -0.82265 USD. Last quarter (2026-02-23) it beat with EPS 13.9 USD vs -0.12662 USD est (+11077.7%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E 3.40.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does LKFT next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.82265 USD
Revenue estimate0.01B

LKFT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-2313.9 USD-0.12662 USD+11077.7%Beat
2025-07-23-1.85303 USD-0.22826 USD-711.8%Miss

Beat rate: 1/2 (50%) over reported quarters with consensus data.

LKFT valuation and analyst view

Trailing P/E3.40
Trailing EPS7.42 USD
Price / book0.51
Dividend yield0.00%
Market cap1.91B
Analyst consensusHold (0 buy / 1 hold / 0 sell)
Avg price target30 USD

Related research pages

Frequently asked questions

When is Lakefront Biotherapeutics (LKFT)'s next earnings date?

Lakefront Biotherapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.82265 USD and revenue estimate of 0.01B.

Did LKFT beat earnings last quarter?

In its 2026-02-23 report, LKFT posted EPS of 13.9 USD versus a -0.12662 USD estimate — a beat of 11077.7%.

What is LKFT's earnings track record?

Over the last 2 reported quarters with consensus data, LKFT beat estimates 1 times (50%).

What is LKFT's current P/E ratio and EPS?

LKFT trades at a trailing P/E of 3.40 on trailing EPS of 7.420051093375867 USD.

What do analysts rate LKFT?

Analyst consensus is "Hold" across 1 ratings (0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 30 USD.